CN105362242A - Eplerenone dispersible tablet - Google Patents
Eplerenone dispersible tablet Download PDFInfo
- Publication number
- CN105362242A CN105362242A CN201510926654.1A CN201510926654A CN105362242A CN 105362242 A CN105362242 A CN 105362242A CN 201510926654 A CN201510926654 A CN 201510926654A CN 105362242 A CN105362242 A CN 105362242A
- Authority
- CN
- China
- Prior art keywords
- eplerenone
- dispersible tablet
- disintegrating agent
- mass percentage
- lubricant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an eplerenone dispersible tablet, which takes eplerenone as an active drug ingredient and uses a disintegrating agent, a cosolvent and an auxiliary additive as non-active ingredients, wherein the disintegrating agent, the cosolvent and the auxiliary additive are common medicinal dispersible tablet dosage adjuvant materials for preparing the dosage form of the dispersible tablet. The eplerenone dispersible tablet disclosed by the invention can overcome the shortcomings of a conventional eplerenone tablet which, due to slow disintegration, is slow in dissolution, insufficient in absorption, not high in bioavailability and the like; the dispersible tablet can rapidly disintegrate in water so as to form a uniform suspension, and the dispersible tablet can rapidly disintegrate and disperse in gastrointestinal tract; a drug distribution area is enlarged, absorption points are increased and absorption is accelerated, and bioavailability is significantly higher than that of the conventional tablet; and the preparation is stable, more convenient to take, low in adverse reactions and is more suitable for patients of hypertension at various ages.
Description
One, technical field
The present invention relates to a kind of pharmaceutical dosage form, specifically a kind of eplerenone dispersible tablet, belongs to medical art.
Two, background technology
Eplerenone (Eplerenone, I) be the selectivity aldosterone antagonists of new generation developed by Pfizer/Pharmacia Corp, be used for the treatment of the hyperpietic of 1 phase and 2 phases, effective percentage is similar to enalapril to the amplitude of diastolic pressure with reduction systolic pressure.To the primary hypertension patient of angiotensin converting enzyme inhibitor and the not good low renin level of angiotensin-ii-receptor depressant effect, eplerenone also has good antihypertensive effect.There is good antihypertensive effect to isolated systolic hypertension, have good hypotensive effect to the hypertension that diet induced obese is correlated with.
Within 2002, first in U.S.'s listing, commodity are called eplerenone conventional tablet:
for the treatment of hypertension, heart failure and myocardial infarction.Have definite curative effect to treatment hypertension, heart failure and myocardial infarction, untoward reaction is less, better tolerance.Its outstanding advantages be to the multiple depressor of coupling fail control severe hypertension, add and blood pressure can be made obviously to reduce with these product, especially systolic pressure decline more remarkable.To severe heart failure and patients with myocardial infarction, these product and angiotensin converting enzyme inhibitor (ACEI) and the coupling of beta 2 receptor blocker can be improved the quality of living and reduce mortality rate.
Eplerenone molecule is not containing ionization structure, and it is almost insoluble in water, therefore for eplerenone oral tablet, its disintegrate rate of dispersion in vivo and bioavailability closely related, and conventional tablet causes stripping slow due to disintegrate slowly, medicine is little at gastrointestinal diffusional area, absorbs insufficient, affect bioavailability, clinical medicine dose increases will be inevitable.Commercially available of Japan
the pharmacokinetic parameter display of Tablets (25mg, 50mg, 100mg) (pharmaceuticals イ Application タ PVC ュ ー Off ォ ー system, 2011 March the 6th edition), it is in yellow race crowd, these product oral 100mg/ time, T
maxh () is 2.3 ± 0.8, C
max(ng/ml) be 1330 ± 236, T
1/2h () is 3.54 ± 0.906, AUC
0-∞(ngh/ml) be 9490 ± 3320, dosage increase and decrease is to T
max, T
1/2affect not obvious, dosage increases and C
max, AUC
0-∞increase disproportionate relation.Show to improve blood drug level by dosage increase, cost dearly, in addition, stripping slowly causes the high and taking dose of local concentration to increase, and easily causes the untoward reaction such as diarrhoea, stomachache.
For improving the bioavailability of eplerenone tablet; patent CN99814110 discloses micronized eplerenone (eplerenone) compositions; by eplerenone micronize is improved eplerenone dissolution velocity in vivo; improve the bioavailability in body; but its disintegration time was more than 6 minutes; at interpolation 1% sodium lauryl sulphate as in the dissolution medium of cosolvent; the stripping result of 15 minutes can only reach about 90%; and this processing step is complicated; raw material needs micronization processes, and production cost is higher.Therefore, be badly in need of finding and a kind ofly can improve bioavailability in eplerenone body and ensure the novel form of its drug safety.
Three, summary of the invention
Existing eplerenone ordinary tablet fully absorbs because disintegrate and stripping affect medicine slowly, and bioavailability is not high, and dosage is large, and cost is high, still has the untoward reaction such as diarrhoea, stomachache, is also unfavorable for that the patient of old man and dysphagia takes.The present invention aims to provide a kind of eplerenone dispersible tablet, to overcome above-mentioned defect.
Inventor, through long-term experimental study, finds eplerenone prepared composition discrete piece, can perfection solve the problem.Dispersible tablet means that meeting water rapidly disintegrate can form the tablet of even aqueous dispersion, is for solving that solid preparation disintegrate is slow, stripping is poor, bioavailability is not high or the problem such as liquid preparation poor stability, packaging, transport, storage inconvenience and a kind of novel form of developing.Be particularly useful for water-insoluble drug, greatly can improve their bioavailability.Except having ordinary tablet good stability, outside the advantage such as to be easy to carry, the advantage taken, bioavailability is higher can be disperseed in addition in water.
Eplerenone dispersible tablet of the present invention is take eplerenone as active constituents of medicine, with disintegrating agent, cosolvent and auxiliary additive for non-active ingredient.
Described disintegrating agent is one or more in cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, polyvinylpolypyrrolidone, carboxymethyl starch sodium, one or both in preferred cross-linking sodium carboxymethyl cellulose and low-substituted hydroxypropyl cellulose, more preferably cross-linking sodium carboxymethyl cellulose and low-substituted hydroxypropyl cellulose, the two mass ratio is 1: 0.1-10, is preferably 1: 0.5-5.
Described cosolvent is one or more in dodecyl sodium sulfate, sodium lauryl sulphate, polysorbate80, polyethylene glycol 6000; Preferably sodium dodecyl sulfate.
Described auxiliary additive comprises filler and lubricant.
Described filler is one or more in lactose, starch, microcrystalline Cellulose, dextrin, mannitol; One or both in preferred lactose and microcrystalline Cellulose; More preferably lactose and microcrystalline Cellulose combination, the two mass ratio is 1: 0.1-10.
Described lubricant is one or more in magnesium stearate, Pulvis Talci, stearic acid, sodium stearyl fumarate; One or both in preferred magnesium stearate and Pulvis Talci; More preferably magnesium stearate and Pulvis Talci, the two ratio is any.
The disintegrating agent that the present invention uses, cosolvent and auxiliary additive are prepares the conventional medicinal dispersing tablets dosage form adjuvant of tablet formulation.
The every sheet weight of described eplerenone dispersible tablet is 100-500mg, and the content of eplerenone dispersible tablet every sheet active constituents of medicine eplerenone is 5-200mg; Be preferably 10-100mg; Most preferably be 10mg, 25mg, 50mg or 100mg.
In described eplerenone dispersible tablet, the mass percentage of disintegrating agent is 5%-40%, and the mass percentage of cosolvent is 1%-5%, and the mass percentage of filler is 50%-85%, and the mass percentage of lubricant is 0.5%-2.5%.
Be preferably:
In described eplerenone dispersible tablet, the mass percentage of disintegrating agent is 5%-10%, and the mass percentage of cosolvent is 1%-3%, and the mass percentage of filler is 70%-80%, and the mass percentage of lubricant is 0.5%-1.5%.
Eplerenone tablet formulation of the present invention, in water, rapid disintegrate forms uniform suspension, in the rapid disintegrate dispersion of gastrointestinal tract, drug distribution enlarged areas, absorption point increases, and absorbs faster, bioavailability is apparently higher than conventional tablet, avoid ordinary preparation high in gastrointestinal tract local drug concentration, the defects such as gastrointestinal mucosa stimulation, adverse reaction reduction simultaneously; Eplerenone tablet formulation of the present invention both can be swallowed as conventional tablet, and also can put into after water disperses rapidly and take, preparation stabilization, effectively can meet the different demands of patient.
Grope through a large amount of prescription screenings and technique, determine the final formulation and technology of eplerenone dispersible tablet, and confirm above-mentioned advantage of the present invention in zoopery and bioequivalence experiment.In research process, inventor finds that specific disintegrating agent is equipped with appropriate cosolvent and is more conducive to this product dispersion stripping uncannily, improves and absorbs, improve bioavailability.Therefore, the present invention includes the selection to disintegrating agent and cosolvent, the disintegrating agent finally selected is one or more in cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, polyvinylpolypyrrolidone, carboxymethyl starch sodium; The cosolvent finally selected is one or more in dodecyl sodium sulfate, sodium lauryl sulphate, polysorbate80, polyethylene glycol 6000.In addition, on the preparation specification basis of listing ordinary tablet, in conjunction with clinical study results, design every sheet eplerenone content at 5-200mg, and (under the condition of temperature 40 DEG C ± 2 DEG C, relative humidity 75% ± 5%, accelerated test investigates 6 months to have carried out stability to 10mg, 25mg, 50mg and 100mg specification, and under the condition of temperature 30 DEG C ± 2 DEG C, relative humidity 65% ± 5%, carry out long term test investigate 36 months) investigate, the every Testing index of result all meets quality standard, confirms its steady quality, controlled.
Human pharmacokinetics is tested: 24 health volunteers are divided into 2 groups at random, the eplerenone dispersible tablet formulation (25mg specification, 4) in one group of oral embodiment prescription 1, other one group of oral eplerenone
ordinary tablet (25mg specification, 4), surveys eplerenone concentration in blood plasma respectively, calculates C
max, T
maxand the parameter such as AUC.Result is as follows:
Result shows: the bioavailability of oral eplerenone dispersible tablet is apparently higher than eplerenone conventional tablet, and dispersible tablet experimenter all finds no obvious adverse reaction.
At prescription screening simultaneously, investigate the preparation technology of eplerenone dispersible tablet, the method preparation that final employing is following:
1, active component eplerenone is crossed 100-200 mesh sieve;
2, mixed homogeneously by equal increments method with non-active ingredient except lubricant by the active component eplerenone after sieving, add purified water moistening soft material, 24 mesh sieves are granulated;
3, wet granular forced air drying at 50-70 DEG C, 20 mesh sieve granulate;
4, lubricant is added, mix homogeneously;
5, tabletting.
The production equipment of eplerenone tablet formulation of the present invention is solid preparation and commonly uses production equipment, and do not need special installation, production cost is lower.Stable preparation process, reproducible.
Four, accompanying drawing explanation
Fig. 1 is prescription 1 In Vitro Dissolution curve;
Fig. 2 is prescription 2 In Vitro Dissolution curve;
Fig. 3 is prescription 3 In Vitro Dissolution curve;
Fig. 4 is prescription 4 In Vitro Dissolution curve;
Fig. 5 is prescription 5 In Vitro Dissolution curve;
Fig. 6 is prescription 6 In Vitro Dissolution curve;
Fig. 7 be commercially available eplerenone sheet (
25mg specification) In Vitro Dissolution curve.
Five, detailed description of the invention
Embodiment 1:
1, prescription 1:(recipe quantity is 1000)
2, preparation technology:
1) active component eplerenone is crossed 200 mesh sieves;
2) take the eplerenone of recipe quantity, add the lactose of recipe quantity, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose and sodium lauryl sulphate successively by equal increments method, mix homogeneously; Add purified water moistening soft material, 24 mesh sieves are granulated;
3) wet granular forced air drying at 50-70 DEG C, 20 mesh sieve granulate;
4) lubricant Pulvis Talci and the magnesium stearate of recipe quantity is added, mix homogeneously;
5) tabletting.
Dispersible tablet prepared by the present embodiment is limited to 48 seconds when disperseing, and dissolution is 99.85%.
Embodiment 2:
1, prescription 2:(recipe quantity is 1000)
2, preparation technology:
1) active component eplerenone is crossed 200 mesh sieves;
2) take the eplerenone of recipe quantity, add the lactose of recipe quantity, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose and sodium lauryl sulphate successively by equal increments method, mix homogeneously; Add purified water moistening soft material, 24 mesh sieves are granulated;
3) wet granular forced air drying at 50-70 DEG C, 20 mesh sieve granulate;
4) lubricant Pulvis Talci and the magnesium stearate of recipe quantity is added, mix homogeneously;
5) tabletting.
The present embodiment prepare dispersible tablet dispersion time be limited to 1 point 19 seconds, dissolution is 98.34%.
Embodiment 3:
1, prescription 3:(recipe quantity is 1000)
2, preparation technology:
1) active component eplerenone is crossed 200 mesh sieves;
2) take the eplerenone of recipe quantity, add the lactose of recipe quantity, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose and sodium lauryl sulphate successively by equal increments method, mix homogeneously; Add purified water moistening soft material, 24 mesh sieves are granulated;
3) wet granular forced air drying at 50-70 DEG C, 20 mesh sieve granulate;
4) lubricant Pulvis Talci and the magnesium stearate of recipe quantity is added, mix homogeneously;
5) tabletting.
The present embodiment prepare dispersible tablet dispersion time be limited to 1 point 54 seconds, dissolution is 98.88%.
Embodiment 4:
1, prescription 4:(recipe quantity is 1000)
2, preparation technology:
1) active component eplerenone is crossed 200 mesh sieves;
2) take the eplerenone of recipe quantity, add the lactose of recipe quantity, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose and sodium lauryl sulphate successively by equal increments method, mix homogeneously; Add purified water moistening soft material, 24 mesh sieves are granulated;
3) wet granular forced air drying at 50-70 DEG C, 20 mesh sieve granulate;
4) lubricant Pulvis Talci and the magnesium stearate of recipe quantity is added, mix homogeneously;
5) tabletting.
The present embodiment prepare dispersible tablet dispersion time be limited to 2 points 33 seconds, dissolution is 99.25%.
Embodiment 5:
1, prescription 5:(recipe quantity is 1000)
2, preparation technology:
1) active component eplerenone is crossed 200 mesh sieves;
2) take the eplerenone of recipe quantity, add the lactose of recipe quantity, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose and sodium lauryl sulphate successively by equal increments method, mix homogeneously; Add purified water moistening soft material, 24 mesh sieves are granulated;
3) wet granular forced air drying at 50-70 DEG C, 20 mesh sieve granulate;
4) lubricant Pulvis Talci and the magnesium stearate of recipe quantity is added, mix homogeneously;
5) tabletting.
Dispersible tablet prepared by the present embodiment is limited to 29 seconds when disperseing, and dissolution is 99.17%.
Embodiment 6:
1, prescription 6:(recipe quantity is 1000)
2, preparation technology:
1) active component eplerenone is crossed 200 mesh sieves;
2) take the eplerenone of recipe quantity, add the lactose of recipe quantity, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose and sodium lauryl sulphate successively by equal increments method, mix homogeneously; Add purified water moistening soft material, 24 mesh sieves are granulated;
3) wet granular forced air drying at 50-70 DEG C, 20 mesh sieve granulate;
4) lubricant Pulvis Talci and the magnesium stearate of recipe quantity is added, mix homogeneously;
5) tabletting.
Dispersible tablet prepared by the present embodiment is limited to 36 seconds when disperseing, and dissolution is 98.79%.
Claims (10)
1. an eplerenone dispersible tablet, is characterized in that: be take eplerenone as active constituents of medicine, with disintegrating agent, cosolvent and auxiliary additive for non-active ingredient;
Described disintegrating agent is one or more in cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, polyvinylpolypyrrolidone, carboxymethyl starch sodium;
Described cosolvent is one or more in dodecyl sodium sulfate, sodium lauryl sulphate, polysorbate80, polyethylene glycol 6000;
Described auxiliary additive comprises filler and lubricant.
2. eplerenone dispersible tablet according to claim 1, is characterized in that:
Described disintegrating agent is one or both in cross-linking sodium carboxymethyl cellulose and low-substituted hydroxypropyl cellulose.
3. eplerenone dispersible tablet according to claim 2, is characterized in that:
Described disintegrating agent is cross-linking sodium carboxymethyl cellulose and low-substituted hydroxypropyl cellulose, and the two mass ratio is 1: 0.1-10.
4. eplerenone dispersible tablet according to claim 1, is characterized in that:
Described filler is one or more in lactose, starch, microcrystalline Cellulose, dextrin, mannitol;
Described lubricant is one or more in magnesium stearate, Pulvis Talci, stearic acid, sodium stearyl fumarate.
5. the eplerenone dispersible tablet according to claim 1 or 4, is characterized in that:
Described filler is one or both in lactose, microcrystalline Cellulose;
Described lubricant is one or both in magnesium stearate, Pulvis Talci.
6. the eplerenone dispersible tablet according to claim 1 or 4, is characterized in that:
Described filler is lactose and microcrystalline Cellulose, and the two mass ratio is 1: 0.1-10;
Described lubricant is magnesium stearate and Pulvis Talci.
7. eplerenone dispersible tablet according to claim 1, is characterized in that:
The every sheet weight of described eplerenone dispersible tablet is 100-500mg; The content of described eplerenone dispersible tablet every sheet active constituents of medicine eplerenone is 5-200mg.
8. eplerenone dispersible tablet according to claim 7, is characterized in that:
The content of described eplerenone dispersible tablet every sheet active constituents of medicine eplerenone is 10-100mg.
9. eplerenone dispersible tablet according to claim 1, is characterized in that:
In described eplerenone dispersible tablet, the mass percentage of disintegrating agent is 5%-40%, and the mass percentage of cosolvent is 1%-5%, and the mass percentage of filler is 50%-85%, and the mass percentage of lubricant is 0.5%-2.5%.
10. eplerenone dispersible tablet according to claim 1, is characterized in that:
In described eplerenone dispersible tablet, the mass percentage of disintegrating agent is 5%-10%, and the mass percentage of cosolvent is 1%-3%, and the mass percentage of filler is 70%-80%, and the mass percentage of lubricant is 0.5%-1.5%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510926654.1A CN105362242B (en) | 2015-12-10 | 2015-12-10 | A kind of eplerenone dispersible tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510926654.1A CN105362242B (en) | 2015-12-10 | 2015-12-10 | A kind of eplerenone dispersible tablet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105362242A true CN105362242A (en) | 2016-03-02 |
| CN105362242B CN105362242B (en) | 2019-04-26 |
Family
ID=55365202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510926654.1A Active CN105362242B (en) | 2015-12-10 | 2015-12-10 | A kind of eplerenone dispersible tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105362242B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107019679A (en) * | 2017-03-27 | 2017-08-08 | 北京万全德众医药生物技术有限公司 | A kind of eplerenone tablet and preparation method thereof |
| CN107456445A (en) * | 2016-06-06 | 2017-12-12 | 南京卡文迪许生物工程技术有限公司 | Eplerenone oral solid formulation and preparation method thereof |
| CN109925293A (en) * | 2019-03-15 | 2019-06-25 | 南京卡文迪许生物工程技术有限公司 | Eplerenone oral solid formulation and preparation method thereof |
| CN113197941A (en) * | 2021-04-16 | 2021-08-03 | 一力制药股份有限公司 | Eplerenone pharmaceutical composition, and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1785286A (en) * | 2005-10-13 | 2006-06-14 | 宁夏启元药业有限公司 | Hawthorm extract fat lowering dispersion tablet and its preparation technology |
| CN101152187A (en) * | 2006-09-29 | 2008-04-02 | 北京德众万全药物技术开发有限公司 | Eplerenone pharmaceutical composition |
| CN102805736A (en) * | 2012-08-31 | 2012-12-05 | 宁夏启元国药有限公司 | Albendazol dispersible tablets and preparation method thereof |
| CN103316056A (en) * | 2013-06-24 | 2013-09-25 | 江苏鹏鹞药业有限公司 | Radix isatidis coating dispersible tablet and preparation method thereof |
-
2015
- 2015-12-10 CN CN201510926654.1A patent/CN105362242B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1785286A (en) * | 2005-10-13 | 2006-06-14 | 宁夏启元药业有限公司 | Hawthorm extract fat lowering dispersion tablet and its preparation technology |
| CN101152187A (en) * | 2006-09-29 | 2008-04-02 | 北京德众万全药物技术开发有限公司 | Eplerenone pharmaceutical composition |
| CN102805736A (en) * | 2012-08-31 | 2012-12-05 | 宁夏启元国药有限公司 | Albendazol dispersible tablets and preparation method thereof |
| CN103316056A (en) * | 2013-06-24 | 2013-09-25 | 江苏鹏鹞药业有限公司 | Radix isatidis coating dispersible tablet and preparation method thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107456445A (en) * | 2016-06-06 | 2017-12-12 | 南京卡文迪许生物工程技术有限公司 | Eplerenone oral solid formulation and preparation method thereof |
| CN107019679A (en) * | 2017-03-27 | 2017-08-08 | 北京万全德众医药生物技术有限公司 | A kind of eplerenone tablet and preparation method thereof |
| CN109925293A (en) * | 2019-03-15 | 2019-06-25 | 南京卡文迪许生物工程技术有限公司 | Eplerenone oral solid formulation and preparation method thereof |
| CN113197941A (en) * | 2021-04-16 | 2021-08-03 | 一力制药股份有限公司 | Eplerenone pharmaceutical composition, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105362242B (en) | 2019-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4868695B2 (en) | Oral preparation with good disintegration | |
| WO2015185013A1 (en) | Pharmaceutical composition containing quinoline derivative or salt thereof, and preparation method therefor | |
| CN105658207A (en) | Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose | |
| EA003266B1 (en) | Micronized eplerenone compositions | |
| CN105362242A (en) | Eplerenone dispersible tablet | |
| WO2008032767A1 (en) | Orally disintegrating tablet and process for production thereof | |
| CN102791271A (en) | Method for improving dissolvability of anticoagulant | |
| CN105213333A (en) | A kind of tadanafil pharmaceutical composition and preparation method thereof | |
| CN105250231A (en) | Drug combination containing etoricoxib and preparation method thereof | |
| CN103006649A (en) | Compound preparation of valsartan amlodipine tablet (I) and preparation method thereof | |
| CN109662949A (en) | A kind of fludrocortisone acetate oral disnitegration tablet and preparation method thereof | |
| CN109875972B (en) | Olmesartan medoxomil and amlodipine pharmaceutical composition | |
| CN107913256A (en) | A kind of macitentan oral disnitegration tablet for treating pulmonary hypertension and preparation method thereof | |
| CN104706640B (en) | A kind of Pharmaceutical composition and its preparation technology containing Irbesartan | |
| CN102755295B (en) | Stability-enhanced medicament composition containing limaprost and preparation method thereof | |
| CN104940152B (en) | A kind of pharmaceutical composition containing butanedioic acid Solifenacin | |
| CN103717209A (en) | Prasugrel-containing immediate release stable oral pharmaceutical compositions | |
| JP2021075686A (en) | Cellulose composition, tablet, and orally disintegrating tablet | |
| CN104644595B (en) | A kind of solid composite medicament containing clopidogrel | |
| JPWO2017047586A1 (en) | tablet | |
| WO2021196982A1 (en) | Anti-arrhythmic pharmaceutical composition and preparation method therefor | |
| CN102335153B (en) | Piperazine ferulate sustained-release tablet and its preparation method | |
| JPH02211A (en) | Pharmacological composition and production thereof | |
| CN112137965A (en) | Cefaclor particle pharmaceutical composition | |
| CN104758932B (en) | A kind of medetofazone compound preparation and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211025 Address after: 230000 room 609-115, R & D center building, China (Hefei) international intelligent voice Industrial Park, 3333 Xiyou Road, high tech Zone, Hefei, Anhui Province Patentee after: Jieruida Pharmaceutical Co.,Ltd. Address before: 230088 8th floor, building 2, Tianyi new century venture building, 16 Hehuan Road, high tech Zone, Hefei City, Anhui Province Patentee before: HEFEI JIUNUO MEDICAL TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230506 Address after: 230088 8th floor, building 2, Tianyi new century venture building, 16 Hehuan Road, high tech Zone, Hefei City, Anhui Province Patentee after: HEFEI JIUNUO MEDICAL TECHNOLOGY Co.,Ltd. Address before: 230000 room 609-115, R & D center building, China (Hefei) international intelligent voice Industrial Park, 3333 Xiyou Road, high tech Zone, Hefei, Anhui Province Patentee before: Jieruida Pharmaceutical Co.,Ltd. |
|
| TR01 | Transfer of patent right |